HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Adenocarcinoma of lung — Clinical Guidelines

Overview

Lung adenocarcinoma is a common subtype of non-small cell lung cancer characterized by glandular differentiation and diverse histological subtypes, impacting prognosis and treatment strategies 5 8.

Diagnosis

Histological Examination: Essential for diagnosis, often requiring assessment of predominant growth patterns (e.g., acinar, papillary, solid, micropapillary, lepidic) 4 10 14.

Molecular Testing: Including EGFR mutations, crucial for guiding targeted therapy 8.

Imaging: CT scans and PET scans for staging and assessing metastasis 12.

Interobserver Variability: Recognized in determining histological patterns; training improves concordance 14.

Management

First-Line Treatments:

- Systemic Therapy: Platinum-based chemotherapy, targeted therapies (e.g., EGFR inhibitors) based on molecular profile 8. - Radiation Therapy: For localized disease or palliation 7.

Adjunctive Treatments:

- Pain Management: Consideration of substance use history, e.g., buprenorphine-naloxone for opioid use disorder 2. - Supportive Care: Management of complications like cardiac cachexia and venous thromboembolism (Trousseau's syndrome) 1 11.

Special Populations

Comorbidities: Management of VTE risk in patients with Trousseau's syndrome, especially in advanced disease 11.

Substance Use: Tailored pain management strategies in patients with opioid use disorder 2.

Key Recommendations

Utilize the 2015 WHO classification for prognostic stratification, distinguishing between subtypes like lepidic, acinar, papillary, and solid/micropapillary adenocarcinomas (Evidence: Strong 5 8).

Incorporate molecular testing, particularly for EGFR mutations, to guide targeted therapy decisions (Evidence: Strong 8).

Enhance interobserver agreement through specialized training in histological classification to improve diagnostic consistency (Evidence: Moderate 14).

Consider comprehensive supportive care measures, including management of complications like cardiac cachexia and VTE, especially in advanced stages (Evidence: Moderate 1 11).

References

1 Fu Z, Lin Z, Chen S, Xie H, Wen H, Huang Y et al.. Cardio-oncology in focus: novel molecular signatures of lung adenocarcinoma-driven cardiac cachexia. Medical oncology (Northwood, London, England) 2025. link 2 Hong S, Zimmerman PE, Rao V, Markwalter DW. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma. Journal of palliative medicine 2023. link 3 Alfaraj DN, Al Dahlawi AM, AlObaid MM, Aldukhayyil TR, Al Rumaih DA. Metastatic Lung Adenocarcinoma: Unusual Presentation with Focal Neurological Deficit. The American journal of case reports 2022. link 4 Wright J, Churg A, Kitaichi M, Yang HM, Hyde D, Yi E. Reproducibility of visual estimation of lung adenocarcinoma subtype proportions. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019. link 5 Mlika M, Helal I, Mrabet A, El Mezni F. Prognostic impact of the 2015 world health organisation classification of lung adenocarcinoma : a study in departement specialized in thoracic pathology. La Tunisie medicale 2018. link 6 Yagi Y, Riedlinger G, Xu X, Nakamura A, Levy B, Iafrate AJ et al.. Development of a database system and image viewer to assist in the correlation of histopathologic features and digital image analysis with clinical and molecular genetic information. Pathology international 2016. link 7 Collisson EA. RB and Prognosis in Resected Lung Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. link 8 Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. The Annals of thoracic surgery 2014. link 9 Campos-Parra AD, Avilés A, Contreras-Reyes S, Rojas-Marín CE, Sánchez-Reyes R, Borbolla-Escoboza RJ et al.. Relevance of the novel IASLC/ATS/ERS classification of lung adenocarcinoma in advanced disease. The European respiratory journal 2014. link 10 Urer HN, Ahiskali R, Arda N, Batur S, Cınel L, Dekan G et al.. Interobserver agreement among histological patterns and diagnosis in lung adenocarcinomas. Turk patoloji dergisi 2014. link 11 Tachihara M, Nikaido T, Wang X, Sato Y, Ishii T, Saito K et al.. Four cases of Trousseau's syndrome associated with lung adenocarcinoma. Internal medicine (Tokyo, Japan) 2012. link 12 Lu CH, Hsiao CH, Chang YC, Lee JM, Shih JY, Wu LA et al.. Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012. link 13 Walts AE, Marchevsky AM. Root cause analysis of problems in the frozen section diagnosis of in situ, minimally invasive, and invasive adenocarcinoma of the lung. Archives of pathology & laboratory medicine 2012. link 14 Warth A, Cortis J, Fink L, Fisseler-Eckhoff A, Geddert H, Hager T et al.. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Archiv : an international journal of pathology 2012. link 15 Saltzman L. Profiles in medicine: tribute to Oscar Auerbach, MD. New Jersey medicine : the journal of the Medical Society of New Jersey 1992. link

Adenocarcinoma of lung